Kivipharm Co., Ltd.

It reduces peripheral vascular resistance, increases cardiac output, reduces venous pressure, activates fibrinolysis, reduces fibrinogen levels, prevents platelet aggregation, promotes the synthesis of pyrimidine nucleosides (NAD and NADP), increases the concentration of adenine nucleosides (AMP, ADP and ATP), and finally hinders lipolysis, reducing elevated cholesterol and triglyceride levels

Not yet clear

It acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis. When used in combination with trimethoprim, it can double-block the bacterial folic acid metabolism and enhance the synergistic antibacterial effect.

It acts on the second step of folic acid anabolism and selectively inhibits the action of dihydrofolate reductase. When used in combination with sulfamethoxazole, it can double-block the bacterial folic acid metabolism and enhance the synergistic antibacterial effect.

It selectively excites the medullary respiratory center and can also act on the carotid body and aortic body chemoreceptors to reflexively excite the respiratory center and increase the respiratory center's sensitivity to carbon dioxide, deepening and accelerating breathing. It has a weak excitatory effect on the vasomotor center. Excessive doses can cause convulsions.